Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer

Breast J. 2020 Mar;26(3):464-468. doi: 10.1111/tbj.13528. Epub 2019 Sep 20.

Abstract

We sought to identify factors associated with disparities in tamoxifen utilization among young patients at high-risk for developing breast cancer. We identified 67 premenopausal, high-risk women age 35-45, without surgical prophylaxis, who did not initiate tamoxifen. Factors associated with noninitiation were examined. About 37% of patients had no documented provider-based discussion regarding initiation. Type of high-risk diagnosis was the only factor associated with a provider-based discussion (P = .03). For patients offered tamoxifen, primary reasons for noninitiation were perceived minimal benefit (66.7%), fertility concerns (16.7%), and concerns about side effects (7.1%). Implementation of comprehensive educational strategies regarding the benefits of tamoxifen should be facilitated to improve initiation among young high-risk patients.

Keywords: chemoprevention; shared decision making; tamoxifen.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / adverse effects
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Middle Aged
  • Premenopause
  • Tamoxifen* / adverse effects

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen